<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe" exact="acute" post="respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome"/>
 <result pre="229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute" exact="respiratory" post="syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS)"/>
 <result pre="(HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory" exact="syndrome" post="(SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus"/>
 <result pre="(HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast" exact="respiratory" post="syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe"/>
 <result pre="severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory" exact="syndrome" post="(MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory"/>
 <result pre="respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe" exact="respiratory" post="and intestinal infections in humans. In this review, we"/>
 <result pre="coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal" exact="infections" post="in humans. In this review, we focus on recent"/>
 <result pre="small-molecule anti-human coronavirus therapies. Introduction Coronaviruses (CoVs) primarily cause multiple" exact="respiratory" post="and intestinal infection in humans and animals [1]. Although"/>
 <result pre="coronavirus therapies. Introduction Coronaviruses (CoVs) primarily cause multiple respiratory and" exact="intestinal infection" post="in humans and animals [1]. Although the history of"/>
 <result pre="therapies. Introduction Coronaviruses (CoVs) primarily cause multiple respiratory and intestinal" exact="infection" post="in humans and animals [1]. Although the history of"/>
 <result pre="were reported in the 1960’s, as causative agents for mild" exact="respiratory" post="infections. Subsequently they were named as (i) human CoV"/>
 <result pre="Kong University 1 (HKU1) 7, 8 (iv) HCoV-NL63, (v) severe" exact="acute" post="respiratory syndrome (SARS)-CoV and (vi) Middle East respiratory syndrome"/>
 <result pre="University 1 (HKU1) 7, 8 (iv) HCoV-NL63, (v) severe acute" exact="respiratory" post="syndrome (SARS)-CoV and (vi) Middle East respiratory syndrome (MERS)-CoV."/>
 <result pre="1 (HKU1) 7, 8 (iv) HCoV-NL63, (v) severe acute respiratory" exact="syndrome" post="(SARS)-CoV and (vi) Middle East respiratory syndrome (MERS)-CoV. The"/>
 <result pre="(v) severe acute respiratory syndrome (SARS)-CoV and (vi) Middle East" exact="respiratory" post="syndrome (MERS)-CoV. The first four CoVs are universally circulated"/>
 <result pre="severe acute respiratory syndrome (SARS)-CoV and (vi) Middle East respiratory" exact="syndrome" post="(MERS)-CoV. The first four CoVs are universally circulated and"/>
 <result pre="humans [9]. However, in severe cases, they can cause life-threatening" exact="pneumonia" post="and bronchiolitis in children and immunocompromised individuals 10, 11,"/>
 <result pre="However, in severe cases, they can cause life-threatening pneumonia and" exact="bronchiolitis" post="in children and immunocompromised individuals 10, 11, 12 such"/>
 <result pre="happened in the Republic of Korea in 2015 [23]. The" exact="virus infection" post="was majorly observed in adults, although it can affect"/>
 <result pre="in the Republic of Korea in 2015 [23]. The virus" exact="infection" post="was majorly observed in adults, although it can affect"/>
 <result pre="it can affect any age of people [24]. Within a" exact="short" post="time, the virus affected a total number of 1401"/>
 <result pre="people [24]. Within a short time, the virus affected a" exact="total" post="number of 1401 individuals, 543 of which died with"/>
 <result pre="an important role in the initial RNA synthesis of the" exact="infectious" post="cycle, template for replication and transcription and as a"/>
 <result pre="(ORFs), ORF1a and ORF1b. These ORFs are then processed by" exact="viral" post="proteases to cleave into 16 non-structural proteins that are"/>
 <result pre="link that they suppress the host immune response to facilitate" exact="viral" post="replication. Figure 2 (A) Structure of coronavirus and (B)"/>
 <result pre="virus entry at the cell membrane during HCoV-229E and SARS-CoV" exact="infection" post="39, 40, 41. Upon the entry, the viral particle"/>
 <result pre="and SARS-CoV infection 39, 40, 41. Upon the entry, the" exact="viral" post="particle is uncoded and ready for translation ORF 1a"/>
 <result pre="drugs and immunomodulators have been used empirically or evaluated in" exact="uncontrolled" post="trials 41, 43, 44, 45, 46, 47, 48, 49,"/>
 <result pre="(1) has been widely used for treating a variety of" exact="viral" post="infections, but for SARS, the clinical outcome of the"/>
 <result pre="see Fig. 4 )- ritonavir (2) and a corticosteroid had" exact="lower" post="21-day acute respiratory distress syndrome (ARDS) and death rates"/>
 <result pre="4 )- ritonavir (2) and a corticosteroid had lower 21-day" exact="acute respiratory distress syndrome" post="(ARDS) and death rates than those who received ribavirin"/>
 <result pre=")- ritonavir (2) and a corticosteroid had lower 21-day acute" exact="respiratory" post="distress syndrome (ARDS) and death rates than those who"/>
 <result pre="(2) and a corticosteroid had lower 21-day acute respiratory distress" exact="syndrome" post="(ARDS) and death rates than those who received ribavirin"/>
 <result pre="saturation and more rapid resolution of radiographic lung opacities than" exact="systemic" post="corticosteroid alone (uncontrolled study) [56]. The use of the"/>
 <result pre="(adjusted OR = 26.0, 95% CI = 4.4–154.8). However, disseminated" exact="fungal infection" post="and avascular osteonecrosis occurred following the prolonged systemic corticosteroid"/>
 <result pre="OR = 26.0, 95% CI = 4.4–154.8). However, disseminated fungal" exact="infection" post="and avascular osteonecrosis occurred following the prolonged systemic corticosteroid"/>
 <result pre="95% CI = 4.4–154.8). However, disseminated fungal infection and avascular" exact="osteonecrosis" post="occurred following the prolonged systemic corticosteroid therapy 57, 58,"/>
 <result pre="disseminated fungal infection and avascular osteonecrosis occurred following the prolonged" exact="systemic" post="corticosteroid therapy 57, 58, 59. A randomized, placebo-controlled study"/>
 <result pre="broadly acting antiviral drugs that have been used for other" exact="viral" post="infections or other indications. These drugs have the obvious"/>
 <result pre="acting antiviral drugs that have been used for other viral" exact="infections" post="or other indications. These drugs have the obvious benefits"/>
 <result pre="have been employed in the management of patients with MERS-CoV" exact="infection" post="[63]. Recently, several research groups reported the discovery of"/>
 <result pre="is the first antipsychotic drug developed for the treatment of" exact="schizophrenia" post="[69] and mechanistically it inhibited the clathrin-mediated endocytosis. It"/>
 <result pre="replication of hepatic C virus [70] (HCV), alphavirus [71], mouse" exact="hepatitis" post="virus (MHV-2) [72] and other coronavirus SARS-CoV [73]. The"/>
 <result pre="orally available small molecule drug used for the treatment of" exact="tumor" post="malignancies through the Src-family of tyrosine kinases (SFKs) inhibition."/>
 <result pre="(EC50 2.4 μM) and HCoV-229E (EC50 5.1 μM), and feline" exact="infectious" post="peritonitis (FIPV, EC50 7.0 μM) within a not-toxic range"/>
 <result pre="2.4 μM) and HCoV-229E (EC50 5.1 μM), and feline infectious" exact="peritonitis" post="(FIPV, EC50 7.0 μM) within a not-toxic range of"/>
 <result pre="agent lopinavir (10) were able to inhibit both MERS-and SARS-CoVs" exact="infection" post="in the low-micromolar range and was linear with the"/>
 <result pre="and dasatinib (36) are known inhibitors of the Abelson murine" exact="leukemia" post="viral oncogene homolog-1 pathway (ABL-1) and were active against"/>
 <result pre="dasatinib (36) are known inhibitors of the Abelson murine leukemia" exact="viral" post="oncogene homolog-1 pathway (ABL-1) and were active against both"/>
 <result pre="suggest that the ABL-1 pathway may be important for the" exact="viral" post="replication and inhibitors of this pathway may have the"/>
 <result pre="coronavirus. Examples include siRNA molecules or inhibitors that target specific" exact="viral" post="enzymes involved in the viral replication cycle, mAbs that"/>
 <result pre="or inhibitors that target specific viral enzymes involved in the" exact="viral" post="replication cycle, mAbs that target the host receptor, inhibitors"/>
 <result pre="1a (pp1a) and pp1ab are processed and cleaved by two" exact="viral" post="proteases, PLpro, and the 3CLpro, to produce non-structural proteins"/>
 <result pre="Inhibitors that target nucleosides or nucleotides are building blocks of" exact="viral" post="nucleic acids and they have broad-spectrum activity against a"/>
 <result pre="exhibits broad-spectrum in vitro anti-viral activity against various viruses, including" exact="hepatitis" post="B virus (HBV), hepatitis C virus (HCV) and arboviruses"/>
 <result pre="anti-viral activity against various viruses, including hepatitis B virus (HBV)," exact="hepatitis" post="C virus (HCV) and arboviruses [82]. Recently, mycophenolic acid"/>
 <result pre="Mycophenolic acid (46) 247.6 222.5 Proteases are indispensable for the" exact="viral" post="life cycle and they play an essential role in"/>
 <result pre="viral life cycle and they play an essential role in" exact="viral" post="replication by mediating the maturation of viral replicases. Therefore,"/>
 <result pre="essential role in viral replication by mediating the maturation of" exact="viral" post="replicases. Therefore, targeting proteases has become an attractive approach"/>
 <result pre="activities in micromolar range without alterations of the normal cell" exact="morphology" post="in confluent HEL cell cultures at concentrations up to"/>
 <result pre="the DEAD-box RNA helicase eIF4A, for MERS-CoV and HCoV-22E on" exact="viral" post="translation using a dual luciferase assay and virus-infected primary"/>
 <result pre="on viral translation using a dual luciferase assay and virus-infected" exact="primary" post="cells [86]. Silvestrol was recently shown to have potent"/>
 <result pre="macrophages. They found that silvestrol is also a potent and" exact="non-toxic" post="inhibitor of cap-dependent viral mRNA translation in CoV-infected human"/>
 <result pre="silvestrol is also a potent and non-toxic inhibitor of cap-dependent" exact="viral" post="mRNA translation in CoV-infected human embryonic lung fibroblast (MRC-5)"/>
 <result pre="cells. It was found to be highly effective against both" exact="infections" post="with EC50 values of 1.3 nM and 3 nM,"/>
 <result pre="the potent antiviral activities of silvestrol were also confirmed using" exact="peripheral" post="blood mononuclear cells (PBMCs) as a second type of"/>
 <result pre="blood mononuclear cells (PBMCs) as a second type of human" exact="primary" post="cells. Mechanistically Silvestrol strongly inhibited the expression of CoV"/>
 <result pre="structural and nonstructural proteins (N, nsp8) and the formation of" exact="viral" post="replication/transcription complexes. They also confirmed that silvestrol found to"/>
 <result pre="involved in proteolytic, deubiquitination, de-ISGylation (ISG = interferon-stimulated gene), and" exact="viral" post="evasion of the innate immune response in addition to"/>
 <result pre="1990s, the compound was used as a reactant for designing" exact="arrhythmia" post="and antiviral drugs as well as compounds set to"/>
 <result pre="picornavirus 3C protease, a family of viruses that also cause" exact="respiratory" post="illness. A broad-spectrum anti-CoV inhibitor N3 (55, peptide derivative,"/>
 <result pre="showed excellent inhibition of MERS-CoV as well as the SARS-CoV" exact="infections" post="(see, for example, compounds 85,86,Fig. 12). Compounds 85 and"/>
 <result pre="1,2,4-triazole derivative 87 (SSYA10-001, see Fig. 12) that inhibited the" exact="viral" post="NTPase/helicase (known as nonstructural protein 13, nsp13) of both"/>
 <result pre="lead for the development of effective broad-spectrum anti-coronavirus drugs. Membrane-bound" exact="viral" post="RNA synthesis inhibitors Like all RNA viruses, coronaviruses employ"/>
 <result pre="RNA viruses, coronaviruses employ host cells membranes to assemble the" exact="viral" post="replicase complex. This evolutionary conserved strategy provides a compartment"/>
 <result pre="replicase complex. This evolutionary conserved strategy provides a compartment for" exact="viral" post="RNA synthesis, a crucial step in the coronavirus life"/>
 <result pre="coronaviral RNA synthesis and showed potent antiviral activity of MERS-CoV" exact="infection" post="with remarkable efficacy [126]. Host-based anti-CoV treatment options The"/>
 <result pre="host innate interferon response is crucial for the control of" exact="viral" post="replication after infection [127]. Although CoVs can suppress the"/>
 <result pre="response is crucial for the control of viral replication after" exact="infection" post="[127]. Although CoVs can suppress the interferon response for"/>
 <result pre="effective antivirals in clinical trials at early stages of the" exact="infection" post="83, 84. Nitazoxanide (89, Fig. 13 ) is another"/>
 <result pre="83, 84. Nitazoxanide (89, Fig. 13 ) is another potent" exact="type I" post="interferon inducer that has been used in humans for"/>
 <result pre="interferon inducer that has been used in humans for parasitic" exact="infections" post="[132]. A synthetic nitrothiazolyl–salicylamide derivative exhibits broad-spectrum antiviral activities"/>
 <result pre="and Phase III clinical trials for the treatment of HCV" exact="infection" post="and influenza and has a good safety profile 132,"/>
 <result pre="the ABL1, ERK-MAPK and/or PI3K-AKT-mTOR pathways, which may block early" exact="viral" post="entry and/or postentry events. However, the major drawback of"/>
 <result pre="Fig. 13) could inhibit more than 90% of MERS-CoV pseudovirus" exact="infection" post="in NBL-7 and Huh-7 cells by interrupting the entry"/>
 <result pre="compounds seem to be safe and effective against various parasitic" exact="infections" post="in animal models and have broad-spectrum activities against enveloped"/>
 <result pre="discovered and characterized as inhibitors of SARS-CoV replication that block" exact="viral" post="entry by three different mechanisms [156]. (i) compound 100"/>
 <result pre="L, a host protease required for processing of SARS-S during" exact="viral" post="entry; and (iii) compound 102 (SSAA09E3) also acts later"/>
 <result pre="enzymatic functions of cathepsin L but prevents fusion of the" exact="viral" post="membrane with the host cellular membrane. Naphthalene sulfonamide derivative"/>
 <result pre="remains incessantly one of the most important etiological factors for" exact="respiratory" post="tract diseases in humans. Recently, it was found that"/>
 <result pre="alga Griffithsia spp. [159]. It binds specifically to oligosaccharides on" exact="viral" post="surface glycoproteins such as S and HIV glycoprotein and"/>
 <result pre="in the properties of lipid membranes and prevent fusion between" exact="viral" post="and target cell membranes. They exhibit broad-spectrum activities against"/>
 <result pre="Fig. 14 ), an approved immunosuppressant in organ transplantation with" exact="limited" post="adverse side effects, has shown in vitro activity against"/>
 <result pre="effects, has shown in vitro activity against HCV and bovine" exact="viral" post="diarrhea virus (BVDV) and was considered as an alternative"/>
 <result pre="has shown in vitro activity against HCV and bovine viral" exact="diarrhea" post="virus (BVDV) and was considered as an alternative to"/>
 <result pre="as an alternative to ribavirin/IFN combinations for treatment of HCV" exact="infections" post="[169] Mizoribine exerts its activity through selective inhibition of"/>
 <result pre="inosine monophosphate synthetase and guanosine monophosphate synthetase, resulting in the" exact="complete" post="inhibition of guanine nucleotide synthesis without incorporation into nucleotides."/>
 <result pre="developed by Gilead Sciences as a treatment for Ebola virus" exact="disease" post="and Marburg virus infections, though it has subsequently also"/>
 <result pre="reasonable antiviral activity against more distantly related viruses such as" exact="respiratory" post="syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus"/>
 <result pre="distantly related viruses such as respiratory syncytial virus, Junin virus," exact="Lassa fever" post="virus, and MERS-coronavirus [170]. Remdesivir was rapidly pushed through"/>
 <result pre="rapidly pushed through clinical trials due to the 2013–2016 West" exact="African" post="Ebola virus epidemic crisis, eventually being used in at"/>
 <result pre="Nipah virus and reduced replication of Nipah virus Malaysia in" exact="primary" post="human lung microvascular endothelial cells by more than four"/>
 <result pre="magnitude, warranting further testing of the efficacy of remdesivir against" exact="Nipah virus infection" post="in vivo. In contrast, to control animals, which all"/>
 <result pre="warranting further testing of the efficacy of remdesivir against Nipah" exact="virus infection" post="in vivo. In contrast, to control animals, which all"/>
 <result pre="further testing of the efficacy of remdesivir against Nipah virus" exact="infection" post="in vivo. In contrast, to control animals, which all"/>
 <result pre="challenge, indicating that remdesivir represents a promising antiviral treatment for" exact="Nipah virus infection" post="also [171]. Conclusions Human coronaviruses utilizes host cellular components"/>
 <result pre="indicating that remdesivir represents a promising antiviral treatment for Nipah" exact="virus infection" post="also [171]. Conclusions Human coronaviruses utilizes host cellular components"/>
 <result pre="that remdesivir represents a promising antiviral treatment for Nipah virus" exact="infection" post="also [171]. Conclusions Human coronaviruses utilizes host cellular components"/>
 <result pre="utilizes host cellular components to achieve various physiological processes, including" exact="viral" post="entry, genomic replication, and the assembly and budding of"/>
 <result pre="damage to the host. Therefore, interrupting any stages of the" exact="viral" post="life cycle would become a potential therapeutic target for"/>
 <result pre="22013Lippincott Williams &amp;amp; Wilkins825858 2CheeverF.S.A murine virus (JHM) causing disseminated" exact="encephalomyelitis" post="with extensive destruction of myelin: I. Isolation and biological"/>
 <result pre="the virusJ. Exp. Med.90194918121018137294 3BaileyO.T.A murine virus (jhm) causing disseminated" exact="encephalomyelitis" post="with extensive destruction of myelin: II. PathologyJ. Exp. Med.90194919521219871701"/>
 <result pre="new antiseptic strategiesViruses420123044306823202515 5HamreD.A new virus isolated from the human" exact="respiratory" post="tractProc. Soc. Exp. Biol. Med.12119661901934285768 6McIntoshK.Recovery in tracheal organ"/>
 <result pre="in tracheal organ cultures of novel viruses from patients with" exact="respiratory" post="diseaseProc. Natl. Acad. Sci. U. S. A.5719679339405231356 7LauS.K.P.Coronavirus HKU1"/>
 <result pre="Natl. Acad. Sci. U. S. A.5719679339405231356 7LauS.K.P.Coronavirus HKU1 and other" exact="coronavirus infections" post="in Hong KongJ. Clin. Microbiol.4420062063207116757599 8VabretA.Detection of the new"/>
 <result pre="Acad. Sci. U. S. A.5719679339405231356 7LauS.K.P.Coronavirus HKU1 and other coronavirus" exact="infections" post="in Hong KongJ. Clin. Microbiol.4420062063207116757599 8VabretA.Detection of the new"/>
 <result pre="HKU1: a report of 6 CasesClin. Infect. Dis.42200663463916447108 9KanwarA.Human coronavirus-HKU1" exact="infection" post="among adults in Cleveland, OhioOpen Forum Infect Dis.422017ofx05228616442 10PeneF.Coronavirus"/>
 <result pre="among adults in Cleveland, OhioOpen Forum Infect Dis.422017ofx05228616442 10PeneF.Coronavirus 229E-related" exact="pneumonia" post="in immunocompromised PatientsClin. Infect. Dis.37200392993213130404 11WalshE.E.Clinical impact of human"/>
 <result pre="Infect. Dis.37200392993213130404 11WalshE.E.Clinical impact of human coronaviruses 229E and OC43" exact="infection" post="in diverse adult populationsJ. Infect. Dis.20820131634164223922367 12GorseG.J.Human coronavirus and"/>
 <result pre="impact of human coronaviruses 229E and OC43 infection in diverse" exact="adult" post="populationsJ. Infect. Dis.20820131634164223922367 12GorseG.J.Human coronavirus and acute respiratory illness"/>
 <result pre="infection in diverse adult populationsJ. Infect. Dis.20820131634164223922367 12GorseG.J.Human coronavirus and" exact="acute" post="respiratory illness in older adults with chronic obstructive pulmonary"/>
 <result pre="in diverse adult populationsJ. Infect. Dis.20820131634164223922367 12GorseG.J.Human coronavirus and acute" exact="respiratory" post="illness in older adults with chronic obstructive pulmonary diseaseJ."/>
 <result pre="12GorseG.J.Human coronavirus and acute respiratory illness in older adults with" exact="chronic" post="obstructive pulmonary diseaseJ. Infect. Dis.199200984785719239338 13WeversB.A.van der HoekL.Recently discovered"/>
 <result pre="and acute respiratory illness in older adults with chronic obstructive" exact="pulmonary" post="diseaseJ. Infect. Dis.199200984785719239338 13WeversB.A.van der HoekL.Recently discovered human coronavirusesClin."/>
 <result pre="Clinical Microbiology9th ed.2007ASM PressWashington D.C14141423 15PyrcK.Antiviral strategies against human coronavirusesInfect." exact="Disorders" post="Drug Targets.720075966 16ArbourN.Neuroinvasion by human respiratory coronavirusesJ. Virol.7420008913892110982334 17ArbourN.Persistent"/>
 <result pre="strategies against human coronavirusesInfect. Disorders Drug Targets.720075966 16ArbourN.Neuroinvasion by human" exact="respiratory" post="coronavirusesJ. Virol.7420008913892110982334 17ArbourN.Persistent infection of human oligodendrocytic and neuroglial"/>
 <result pre="Disorders Drug Targets.720075966 16ArbourN.Neuroinvasion by human respiratory coronavirusesJ. Virol.7420008913892110982334 17ArbourN.Persistent" exact="infection" post="of human oligodendrocytic and neuroglial cell lines by human"/>
 <result pre="cell lines by human coronavirus 229EJ. Virol.7319993326333710074187 18JacomyH.Human coronavirus OC43" exact="infection" post="induces chronic encephalitis leading to disabilities in BALB/C miceVirology349200633534616527322"/>
 <result pre="by human coronavirus 229EJ. Virol.7319993326333710074187 18JacomyH.Human coronavirus OC43 infection induces" exact="chronic" post="encephalitis leading to disabilities in BALB/C miceVirology349200633534616527322 19VabretA.An outbreak"/>
 <result pre="human coronavirus 229EJ. Virol.7319993326333710074187 18JacomyH.Human coronavirus OC43 infection induces chronic" exact="encephalitis" post="leading to disabilities in BALB/C miceVirology349200633534616527322 19VabretA.An outbreak of"/>
 <result pre="to disabilities in BALB/C miceVirology349200633534616527322 19VabretA.An outbreak of coronavirus OC43" exact="respiratory" post="infection in Normandy, FranceClin. Infect. Dis.36200398598912684910 20SmutsH.Human coronavirus NL63"/>
 <result pre="disabilities in BALB/C miceVirology349200633534616527322 19VabretA.An outbreak of coronavirus OC43 respiratory" exact="infection" post="in Normandy, FranceClin. Infect. Dis.36200398598912684910 20SmutsH.Human coronavirus NL63 infections"/>
 <result pre="respiratory infection in Normandy, FranceClin. Infect. Dis.36200398598912684910 20SmutsH.Human coronavirus NL63" exact="infections" post="in infants hospitalised with acute respiratory tract infections in"/>
 <result pre="Infect. Dis.36200398598912684910 20SmutsH.Human coronavirus NL63 infections in infants hospitalised with" exact="acute" post="respiratory tract infections in South AfricaInfluenza Other Respir. Viruses2200813513819453465"/>
 <result pre="Dis.36200398598912684910 20SmutsH.Human coronavirus NL63 infections in infants hospitalised with acute" exact="respiratory" post="tract infections in South AfricaInfluenza Other Respir. Viruses2200813513819453465 21Communicable"/>
 <result pre="coronavirus NL63 infections in infants hospitalised with acute respiratory tract" exact="infections" post="in South AfricaInfluenza Other Respir. Viruses2200813513819453465 21Communicable Disease Surveillance"/>
 <result pre="respiratory tract infections in South AfricaInfluenza Other Respir. Viruses2200813513819453465 21Communicable" exact="Disease" post="Surveillance and Response2003World Health Organization659_TD$DIFF]GenevaMay 7, 2003; http://www.who.int/csr/sars/archive/2003_05_07a/en and"/>
 <result pre="and http://www.who.int/csr/sars/country/ en/country2003_08_15.pdf (August 15) 22ParkS.Y.Post-exposure prophylaxis for Middle East" exact="respiratory" post="syndrome in healthcare workersJ. Hosp. Infect.1012019424630240813 23WHOMiddle East respiratory"/>
 <result pre="http://www.who.int/csr/sars/country/ en/country2003_08_15.pdf (August 15) 22ParkS.Y.Post-exposure prophylaxis for Middle East respiratory" exact="syndrome" post="in healthcare workersJ. Hosp. Infect.1012019424630240813 23WHOMiddle East respiratory syndrome"/>
 <result pre="East respiratory syndrome in healthcare workersJ. Hosp. Infect.1012019424630240813 23WHOMiddle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) summary and literature update-as of 20"/>
 <result pre="respiratory syndrome in healthcare workersJ. Hosp. Infect.1012019424630240813 23WHOMiddle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) summary and literature update-as of 20 January2014Geneva,"/>
 <result pre="summary and literature update-as of 20 January2014Geneva, SwitzerlandWHO 24Centers for" exact="Disease" post="Control and PreventionMiddle East respiratory syndrome (MERS)Available at: https://www.cdc.gov/coronavirus/mers/index.html"/>
 <result pre="20 January2014Geneva, SwitzerlandWHO 24Centers for Disease Control and PreventionMiddle East" exact="respiratory" post="syndrome (MERS)Available at: https://www.cdc.gov/coronavirus/mers/index.html (Accessed 17 April 2019).2017 25World"/>
 <result pre="January2014Geneva, SwitzerlandWHO 24Centers for Disease Control and PreventionMiddle East respiratory" exact="syndrome" post="(MERS)Available at: https://www.cdc.gov/coronavirus/mers/index.html (Accessed 17 April 2019).2017 25World Health"/>
 <result pre="(Accessed 17 April 2019).2017 25World Health OrganizationClinical mamagment of severe" exact="acute" post="respiratory infection when MERS-CoV infection is suspected: interim guidanceAvailable"/>
 <result pre="17 April 2019).2017 25World Health OrganizationClinical mamagment of severe acute" exact="respiratory" post="infection when MERS-CoV infection is suspected: interim guidanceAvailable at:"/>
 <result pre="April 2019).2017 25World Health OrganizationClinical mamagment of severe acute respiratory" exact="infection" post="when MERS-CoV infection is suspected: interim guidanceAvailable at: http://www.who.int/iris/handle/10665/178529"/>
 <result pre="Health OrganizationClinical mamagment of severe acute respiratory infection when MERS-CoV" exact="infection" post="is suspected: interim guidanceAvailable at: http://www.who.int/iris/handle/10665/178529 (Accessed 17 April"/>
 <result pre="PressMassachusetts, MA, USA193292 31CottonM.Transmission and evolution of the Middle East" exact="respiratory" post="syndrome coronavirus in Saudi Arabia: a descriptive genomic studyLancet382199320132002"/>
 <result pre="MA, USA193292 31CottonM.Transmission and evolution of the Middle East respiratory" exact="syndrome" post="coronavirus in Saudi Arabia: a descriptive genomic studyLancet382199320132002 32YeagerC.L.Human"/>
 <result pre="and employs hemagglutinin-esterase protein as a receptor-destroying enzymeJ. Virol.8920157202721325926653 34ButlerN.Murine" exact="encephalitis" post="caused by HCoV-OC43, a human coronavirus with broad species"/>
 <result pre="coronavirusNature426200345045414647384 36LiW.The S proteins of human coronavirus NL63 and severe" exact="acute" post="respiratory syndrome coronavirus bind overlapping regions of ACE2Virology367200736737417631932 37WuK.Crystal"/>
 <result pre="36LiW.The S proteins of human coronavirus NL63 and severe acute" exact="respiratory" post="syndrome coronavirus bind overlapping regions of ACE2Virology367200736737417631932 37WuK.Crystal structure"/>
 <result pre="S proteins of human coronavirus NL63 and severe acute respiratory" exact="syndrome" post="coronavirus bind overlapping regions of ACE2Virology367200736737417631932 37WuK.Crystal structure of"/>
 <result pre="coronavirus bind overlapping regions of ACE2Virology367200736737417631932 37WuK.Crystal structure of NL63" exact="respiratory" post="coronavirus receptor-binding domain complexed with its human receptorProc. Natl."/>
 <result pre="U. S. A.1062009199701997419901337 38Van DoremalenN.Host species restriction of Middle East" exact="respiratory" post="syndrome coronavirus through its receptor, dipeptidyl peptidaseJ. Virol.8820149220923224899185 39BertramS.TMPRSS2"/>
 <result pre="S. A.1062009199701997419901337 38Van DoremalenN.Host species restriction of Middle East respiratory" exact="syndrome" post="coronavirus through its receptor, dipeptidyl peptidaseJ. Virol.8820149220923224899185 39BertramS.TMPRSS2 activates"/>
 <result pre="229E for cathepsin-independent host cell entry and is expressed in" exact="viral" post="target cells in the respiratory epitheliumJ. Virol.8720136150616023536651 40BertramS.cleavage and"/>
 <result pre="entry and is expressed in viral target cells in the" exact="respiratory" post="epitheliumJ. Virol.8720136150616023536651 40BertramS.cleavage and activation of the severe acute"/>
 <result pre="the respiratory epitheliumJ. Virol.8720136150616023536651 40BertramS.cleavage and activation of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein by human airway trypsin-like"/>
 <result pre="respiratory epitheliumJ. Virol.8720136150616023536651 40BertramS.cleavage and activation of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein by human airway trypsin-like proteaseJ."/>
 <result pre="epitheliumJ. Virol.8720136150616023536651 40BertramS.cleavage and activation of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein by human airway trypsin-like proteaseJ. Virol.852011133631337221994442"/>
 <result pre="coronavirus spike protein by human airway trypsin-like proteaseJ. Virol.852011133631337221994442 41ChengV.C.Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
 <result pre="spike protein by human airway trypsin-like proteaseJ. Virol.852011133631337221994442 41ChengV.C.Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
 <result pre="protein by human airway trypsin-like proteaseJ. Virol.852011133631337221994442 41ChengV.C.Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infectionClin."/>
 <result pre="agent of emerging and reemerging infectionClin. Microbiol. Rev.20200766069417934078 42ChanJ.F.Middle East" exact="respiratory" post="syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseClin. Microbiol."/>
 <result pre="of emerging and reemerging infectionClin. Microbiol. Rev.20200766069417934078 42ChanJ.F.Middle East respiratory" exact="syndrome" post="coronavirus: another zoonotic betacoronavirus causing SARS-like diseaseClin. Microbiol. Rev.28201546552225810418"/>
 <result pre="causing SARS-like diseaseClin. Microbiol. Rev.28201546552225810418 43LeeN.A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong KongN. Engl. J. Med.34820031986199412682352 44BoothC.M.Clinical"/>
 <result pre="SARS-like diseaseClin. Microbiol. Rev.28201546552225810418 43LeeN.A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong KongN. Engl. J. Med.34820031986199412682352 44BoothC.M.Clinical features"/>
 <result pre="diseaseClin. Microbiol. Rev.28201546552225810418 43LeeN.A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong KongN. Engl. J. Med.34820031986199412682352 44BoothC.M.Clinical features and"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ."/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ. Infect. Dis.2112015809025030060"/>
 <result pre="meta-analysisJ. Infect. Dis.2112015809025030060 46OmraniA.S.Ribavirin and interferonα2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221"/>
 <result pre="Infect. Dis.2112015809025030060 46OmraniA.S.Ribavirin and interferonα2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 47Al-TawfiqJ.A.Ribavirin"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: an observational studyInt. J. Infect. Dis.202014424624406736 48KhalidM.Ribavirin"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: an observational studyInt. J. Infect. Dis.202014424624406736 48KhalidM.Ribavirin and"/>
 <result pre="an observational studyInt. J. Infect. Dis.202014424624406736 48KhalidM.Ribavirin and interferon-α-2b as" exact="primary" post="and preventive treatment for Middle East respiratory syndrome coronavirus"/>
 <result pre="and interferon-α-2b as primary and preventive treatment for Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV): a preliminary report of two casesAntivir."/>
 <result pre="interferon-α-2b as primary and preventive treatment for Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV): a preliminary report of two casesAntivir. Ther.202015879124831606"/>
 <result pre="or IFN-β1a in combination with ribavirin to treat Middle East" exact="respiratory" post="syndrome coronavirus pneumonia: a retrospective studyJ. Antimicrob. Chemother.7020152129213225900158 50SpanakisN.Virological"/>
 <result pre="IFN-β1a in combination with ribavirin to treat Middle East respiratory" exact="syndrome" post="coronavirus pneumonia: a retrospective studyJ. Antimicrob. Chemother.7020152129213225900158 50SpanakisN.Virological and"/>
 <result pre="Chemother.7020152129213225900158 50SpanakisN.Virological and serological analysis of a recent Middle East" exact="respiratory" post="syndrome coronavirus infection case on a triple combination antiviral"/>
 <result pre="50SpanakisN.Virological and serological analysis of a recent Middle East respiratory" exact="syndrome" post="coronavirus infection case on a triple combination antiviral regimenInt."/>
 <result pre="and serological analysis of a recent Middle East respiratory syndrome" exact="coronavirus infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
 <result pre="triple combination antiviral regimenInt. J. Antimicrob. Agents44201452853225288266 51ChengV.C.Medical treatment of" exact="viral pneumonia" post="including SARS in immunocompetent adultJ. Infect.49200426227315474623 52ChengV.C.Clinical management and"/>
 <result pre="combination antiviral regimenInt. J. Antimicrob. Agents44201452853225288266 51ChengV.C.Medical treatment of viral" exact="pneumonia" post="including SARS in immunocompetent adultJ. Infect.49200426227315474623 52ChengV.C.Clinical management and"/>
 <result pre="pneumonia including SARS in immunocompetent adultJ. Infect.49200426227315474623 52ChengV.C.Clinical management and" exact="infection" post="control of SARS: lessons learnedAntiviral Res.100201340741923994190 53WongS.S.The management of"/>
 <result pre="infection control of SARS: lessons learnedAntiviral Res.100201340741923994190 53WongS.S.The management of" exact="coronavirus infections" post="with particular reference to SARSJ. Antimicrob. Chemother.62200843744118565970 54ChanK.S.Treatment of"/>
 <result pre="control of SARS: lessons learnedAntiviral Res.100201340741923994190 53WongS.S.The management of coronavirus" exact="infections" post="with particular reference to SARSJ. Antimicrob. Chemother.62200843744118565970 54ChanK.S.Treatment of"/>
 <result pre="with particular reference to SARSJ. Antimicrob. Chemother.62200843744118565970 54ChanK.S.Treatment of severe" exact="acute" post="respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort"/>
 <result pre="particular reference to SARSJ. Antimicrob. Chemother.62200843744118565970 54ChanK.S.Treatment of severe acute" exact="respiratory" post="syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong"/>
 <result pre="reference to SARSJ. Antimicrob. Chemother.62200843744118565970 54ChanK.S.Treatment of severe acute respiratory" exact="syndrome" post="with lopinavir/ritonavir: a multicentre retrospective matched cohort studyHong Kong"/>
 <result pre="virological and clinical findingsThorax59200425225614985565 56LoutfyM.R.Interferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary studyJAMA29020033222322814693875 57WangH.Fatal aspergillosis in a"/>
 <result pre="and clinical findingsThorax59200425225614985565 56LoutfyM.R.Interferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary studyJAMA29020033222322814693875 57WangH.Fatal aspergillosis in a patient"/>
 <result pre="corticosteroids in severe acute respiratory syndrome: a preliminary studyJAMA29020033222322814693875 57WangH.Fatal" exact="aspergillosis" post="in a patient with SARS who was treated with"/>
 <result pre="Med.349200350750812890854 58GriffithJ.F.Osteonecrosis of hip and knee in patients with severe" exact="acute" post="respiratory syndrome treated with steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as"/>
 <result pre="58GriffithJ.F.Osteonecrosis of hip and knee in patients with severe acute" exact="respiratory" post="syndrome treated with steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as predictor"/>
 <result pre="of hip and knee in patients with severe acute respiratory" exact="syndrome" post="treated with steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as predictor for"/>
 <result pre="treated with steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as predictor for severe" exact="acute" post="respiratory syndrome mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute"/>
 <result pre="with steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute" exact="respiratory" post="syndrome mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute respiratory"/>
 <result pre="steroidsRadiology235200516817515703312 59TsangO.T.Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory" exact="syndrome" post="mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute respiratory syndrome"/>
 <result pre="severe acute respiratory syndrome mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe" exact="acute" post="respiratory syndrome coronaviruschemotherapyFuture Virol.6201161563121765859 61ChengV.C.Severeacute respiratory syndrome coronavirus as"/>
 <result pre="acute respiratory syndrome mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute" exact="respiratory" post="syndrome coronaviruschemotherapyFuture Virol.6201161563121765859 61ChengV.C.Severeacute respiratory syndrome coronavirus as an"/>
 <result pre="respiratory syndrome mortalityEmerg. Infect. Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute respiratory" exact="syndrome" post="coronaviruschemotherapyFuture Virol.6201161563121765859 61ChengV.C.Severeacute respiratory syndrome coronavirus as an agentof"/>
 <result pre="Dis.920031381138714718079 60BarnardD.L.Recent developments inanti-severe acute respiratory syndrome coronaviruschemotherapyFuture Virol.6201161563121765859 61ChengV.C.Severeacute" exact="respiratory" post="syndrome coronavirus as an agentof emerging and reemergin infectionClin."/>
 <result pre="60BarnardD.L.Recent developments inanti-severe acute respiratory syndrome coronaviruschemotherapyFuture Virol.6201161563121765859 61ChengV.C.Severeacute respiratory" exact="syndrome" post="coronavirus as an agentof emerging and reemergin infectionClin. Microbiol."/>
 <result pre="against coronaviruses: developing [735_TD$DIFF]virusspecific and broad-spectrum inhibitorsAntiviral Res.101201410511224269477 63McIntoshK.Middle East" exact="respiratory" post="syndrome coronavirus: treatment and prevention2017https://www.uptodate.com/contents/middle-east-respiratory-syndrome-coronavirus-virology-pathogenesis-and-epidemiology 64[741_TD$DIFF]ShenHigh-throughput screening and identification"/>
 <result pre="coronaviruses: developing [735_TD$DIFF]virusspecific and broad-spectrum inhibitorsAntiviral Res.101201410511224269477 63McIntoshK.Middle East respiratory" exact="syndrome" post="coronavirus: treatment and prevention2017https://www.uptodate.com/contents/middle-east-respiratory-syndrome-coronavirus-virology-pathogenesis-and-epidemiology 64[741_TD$DIFF]ShenHigh-throughput screening and identification of"/>
 <result pre="East respiratorysyndromecoronavirus replication in cell cultureAntimicrobAgentsChemother58201448754884 66SavarinoA.Effects of chloroquine on" exact="viral" post="infections: an old drug against today’s diseases?Lancet Infect. Dis.3200372272714592603"/>
 <result pre="table Chikungunya replicon cell line and virus-based assaysPLoS One62011e28923 72PuY.Mouse" exact="hepatitis" post="virus type 2 enters cells through a clathrin-mediated endocytic"/>
 <result pre="replicon cell line and virus-based assaysPLoS One62011e28923 72PuY.Mouse hepatitis virus" exact="type 2" post="enters cells through a clathrin-mediated endocytic pathway independent of"/>
 <result pre="endocytic pathway independent of Eps15J. Virol8220088112812318550663 73InoueY.Clathrin-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus into target cells expressing ACE2 with"/>
 <result pre="pathway independent of Eps15J. Virol8220088112812318550663 73InoueY.Clathrin-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus into target cells expressing ACE2 with the"/>
 <result pre="independent of Eps15J. Virol8220088112812318550663 73InoueY.Clathrin-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus into target cells expressing ACE2 with the cytoplasmic"/>
 <result pre="deletedJ. Virol.8120078722872917522231 74RegnardC.LoperamideJ. Pain Symptom Manage.42201131932321703817 75WuC.Y.Small molecules targeting severe" exact="acute" post="respiratory syndrome human coronavirusProc. Natl. Acad. Sci. U. S."/>
 <result pre="Virol.8120078722872917522231 74RegnardC.LoperamideJ. Pain Symptom Manage.42201131932321703817 75WuC.Y.Small molecules targeting severe acute" exact="respiratory" post="syndrome human coronavirusProc. Natl. Acad. Sci. U. S. A.1012004100121001715226499"/>
 <result pre="74RegnardC.LoperamideJ. Pain Symptom Manage.42201131932321703817 75WuC.Y.Small molecules targeting severe acute respiratory" exact="syndrome" post="human coronavirusProc. Natl. Acad. Sci. U. S. A.1012004100121001715226499 76ShinJ.S.Saracatinib"/>
 <result pre="Natl. Acad. Sci. U. S. A.1012004100121001715226499 76ShinJ.S.Saracatinib inhibits Middle East" exact="respiratory" post="syndrome-coronavirus replication in vitroViruses102018283 77PlunkettW.Gemcitabine: metabolism, mechanisms of action,"/>
 <result pre="virus, and dengue virusCell13920091243125420064371 80BoschB.J.Cathepsin L functionally cleaves the severe" exact="acute" post="respiratory syndrome coronavirus class I fusion protein upstream of"/>
 <result pre="and dengue virusCell13920091243125420064371 80BoschB.J.Cathepsin L functionally cleaves the severe acute" exact="respiratory" post="syndrome coronavirus class I fusion protein upstream of rather"/>
 <result pre="dengue virusCell13920091243125420064371 80BoschB.J.Cathepsin L functionally cleaves the severe acute respiratory" exact="syndrome" post="coronavirus class I fusion protein upstream of rather than"/>
 <result pre="adjacent to the fusion peptideJ. Virol.8220088887889018562523 81LiuQ.Testing of Middle East" exact="respiratory" post="syndrome coronavirus replication inhibitors for the ability to block"/>
 <result pre="to the fusion peptideJ. Virol.8220088887889018562523 81LiuQ.Testing of Middle East respiratory" exact="syndrome" post="coronavirus replication inhibitors for the ability to block viral"/>
 <result pre="respiratory syndrome coronavirus replication inhibitors for the ability to block" exact="viral" post="entryAntimicrob Agents Chemother59201574274425331705 82van BoheemenS.Genomic characterization of a newly"/>
 <result pre="82van BoheemenS.Genomic characterization of a newly discovered coronavirus associated with" exact="acute respiratory distress syndrome" post="in humansmBio32012e004731223170002 83ChanJ.F.Broad-spectrum antivirals for the emerging Middle East"/>
 <result pre="BoheemenS.Genomic characterization of a newly discovered coronavirus associated with acute" exact="respiratory" post="distress syndrome in humansmBio32012e004731223170002 83ChanJ.F.Broad-spectrum antivirals for the emerging"/>
 <result pre="of a newly discovered coronavirus associated with acute respiratory distress" exact="syndrome" post="in humansmBio32012e004731223170002 83ChanJ.F.Broad-spectrum antivirals for the emerging Middle East"/>
 <result pre="syndrome in humansmBio32012e004731223170002 83ChanJ.F.Broad-spectrum antivirals for the emerging Middle East" exact="respiratory" post="syndrome coronavirusJ. Infect.67201360661624096239 84ChanJ.F.Treatment with lopinavir/ritonavir or interferon-β1b improves"/>
 <result pre="in humansmBio32012e004731223170002 83ChanJ.F.Broad-spectrum antivirals for the emerging Middle East respiratory" exact="syndrome" post="coronavirusJ. Infect.67201360661624096239 84ChanJ.F.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome"/>
 <result pre="Infect.67201360661624096239 84ChanJ.F.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV" exact="infection" post="in a non-human primate model of common marmosetJ. Infect."/>
 <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res.228201771327840112 88MielechA.M.MERS-CoV papain-like protease has"/>
 <result pre="mycophenolic acid synergistically inhibit the papain-like protease of Middle East" exact="respiratory" post="syndrome coronavirusAntiviral Res.115201591625542975 93ParanjpeA.Disulfiram is a direct and potent"/>
 <result pre="acid synergistically inhibit the papain-like protease of Middle East respiratory" exact="syndrome" post="coronavirusAntiviral Res.115201591625542975 93ParanjpeA.Disulfiram is a direct and potent inhibitor"/>
 <result pre="direct and potent inhibitor of human o6-methylguanine-DNA methyltransferase (mgmt) in" exact="brain tumor" post="cells and mouse brain and markedly increases the alkylating"/>
 <result pre="and potent inhibitor of human o6-methylguanine-DNA methyltransferase (mgmt) in brain" exact="tumor" post="cells and mouse brain and markedly increases the alkylating"/>
 <result pre="a series of novel and reversible inhibitors for the severe" exact="acute" post="respiratory syndrome-coronavirus papain-like proteaseJ. Med. Chem.5220095228524019645480 100GhoshA.K.Severe acute respiratory"/>
 <result pre="series of novel and reversible inhibitors for the severe acute" exact="respiratory" post="syndrome-coronavirus papain-like proteaseJ. Med. Chem.5220095228524019645480 100GhoshA.K.Severe acute respiratory syndrome"/>
 <result pre="the severe acute respiratory syndrome-coronavirus papain-like proteaseJ. Med. Chem.5220095228524019645480 100GhoshA.K.Severe" exact="acute" post="respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis,"/>
 <result pre="severe acute respiratory syndrome-coronavirus papain-like proteaseJ. Med. Chem.5220095228524019645480 100GhoshA.K.Severe acute" exact="respiratory" post="syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand"/>
 <result pre="acute respiratory syndrome-coronavirus papain-like proteaseJ. Med. Chem.5220095228524019645480 100GhoshA.K.Severe acute respiratory" exact="syndrome" post="coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray"/>
 <result pre="inhibitor targeting a 3C-like proteaseProtein Cell4201324825023549610 105ShieJ.J.Inhibition of the severe" exact="acute" post="respiratory syndrome 3CL protease by peptidomimetic alpha, beta-unsaturated estersBioorg."/>
 <result pre="targeting a 3C-like proteaseProtein Cell4201324825023549610 105ShieJ.J.Inhibition of the severe acute" exact="respiratory" post="syndrome 3CL protease by peptidomimetic alpha, beta-unsaturated estersBioorg. Med."/>
 <result pre="a 3C-like proteaseProtein Cell4201324825023549610 105ShieJ.J.Inhibition of the severe acute respiratory" exact="syndrome" post="3CL protease by peptidomimetic alpha, beta-unsaturated estersBioorg. Med. Chem.1320055240525215994085"/>
 <result pre="proteaseCurr. Top. Med. Chem.6200636137616611148 107GhoshA.K.Design and synthesis of peptidomimetic severe" exact="acute" post="respiratory syndrome chymotrypsin-like protease inhibitorsJ. Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of"/>
 <result pre="Top. Med. Chem.6200636137616611148 107GhoshA.K.Design and synthesis of peptidomimetic severe acute" exact="respiratory" post="syndrome chymotrypsin-like protease inhibitorsJ. Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(-(benzyl)acetamido)phenyl)"/>
 <result pre="Med. Chem.6200636137616611148 107GhoshA.K.Design and synthesis of peptidomimetic severe acute respiratory" exact="syndrome" post="chymotrypsin-like protease inhibitorsJ. Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(-(benzyl)acetamido)phenyl) carboxamides"/>
 <result pre="protease inhibitorsJ. Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(-(benzyl)acetamido)phenyl) carboxamides as severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300"/>
 <result pre="inhibitorsJ. Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(-(benzyl)acetamido)phenyl) carboxamides as severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and"/>
 <result pre="Med. Chem.4820056767677116250632 108TurlingtonM.Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent"/>
 <result pre="Med. Chem. Lett.1720075876588017855091 110KumarV.Identification and evaluation of potent middle east" exact="respiratory" post="syndrome coronavirus (mers-cov) 3cl(pro) inhibitorsAntivir. Res.141201710110628216367 111TomarS.Ligand-induced dimerization of"/>
 <result pre="Chem. Lett.1720075876588017855091 110KumarV.Identification and evaluation of potent middle east respiratory" exact="syndrome" post="coronavirus (mers-cov) 3cl(pro) inhibitorsAntivir. Res.141201710110628216367 111TomarS.Ligand-induced dimerization of MERS"/>
 <result pre="protease inhibitorsBioorg. Med. Chem.2420163035304227240464 115KimY.Reversal of the progression of fatal" exact="coronavirus infection" post="in cats by a broad-spectrum coronavirus protease inhibitorPLoS Pathog.122016e1005531"/>
 <result pre="inhibitorsBioorg. Med. Chem.2420163035304227240464 115KimY.Reversal of the progression of fatal coronavirus" exact="infection" post="in cats by a broad-spectrum coronavirus protease inhibitorPLoS Pathog.122016e1005531"/>
 <result pre="inhibitor of SARS, MHV and MERS coronavirusesAntimicrob. Agents Chemother.5820144894489824841268 124AdedejiA.O.Severe" exact="acute" post="respiratory syndrome coronavirus replication inhibitor that interferes with the"/>
 <result pre="of SARS, MHV and MERS coronavirusesAntimicrob. Agents Chemother.5820144894489824841268 124AdedejiA.O.Severe acute" exact="respiratory" post="syndrome coronavirus replication inhibitor that interferes with the nucleic"/>
 <result pre="SARS, MHV and MERS coronavirusesAntimicrob. Agents Chemother.5820144894489824841268 124AdedejiA.O.Severe acute respiratory" exact="syndrome" post="coronavirus replication inhibitor that interferes with the nucleic acid"/>
 <result pre="inhibitor that interferes with the nucleic acid unwinding of the" exact="viral" post="helicaseAntimicrob. Agents Chemother.5620124718472822733076 125LeeH.J.Hesperidin, A Popular Antioxidant Inhibits Melanogenesis"/>
 <result pre="suppression of innate antiviral response by the novel Middle East" exact="respiratory" post="syndrome coronavirus: implications for pathogenesis and treatmentJ. Gen. Virol.9420132679269024077366"/>
 <result pre="of innate antiviral response by the novel Middle East respiratory" exact="syndrome" post="coronavirus: implications for pathogenesis and treatmentJ. Gen. Virol.9420132679269024077366 129JossetL.Cell"/>
 <result pre="for pathogenesis and treatmentJ. Gen. Virol.9420132679269024077366 129JossetL.Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
 <result pre="antivirals and important differences with SARS coronavirusmBio42013e00165–e00113 130HaagmansB.L.Pegylated interferon-α protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β"/>
 <result pre="SARS coronavirusmBio42013e00165–e00113 130HaagmansB.L.Pegylated interferon-α protects type 1 pneumocytes against SARS" exact="coronavirus infection" post="in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β and mycophenolic acid are potent"/>
 <result pre="coronavirusmBio42013e00165–e00113 130HaagmansB.L.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β and mycophenolic acid are potent"/>
 <result pre="131HartB.J.Interferon-β and mycophenolic acid are potent inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus in cell-based assaysJ. Gen. Virol.95201457157724323636 132RossignolJ.F.Nitazoxanide: a"/>
 <result pre="and mycophenolic acid are potent inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus in cell-based assaysJ. Gen. Virol.95201457157724323636 132RossignolJ.F.Nitazoxanide: a first-in-class"/>
 <result pre="135ChannappanavarR.Protective effect of intranasal regimens containing peptidic Middle East [871_TD$DIFF]Respiratory" exact="Syndrome" post="coronavirus fusion inhibitor against MERS-CoV infectionJ. Infect. Dis.212200318941903 136OmraniA.S.Ribavirin"/>
 <result pre="infectionJ. Infect. Dis.212200318941903 136OmraniA.S.Ribavirin and interferonα-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221"/>
 <result pre="Infect. Dis.212200318941903 136OmraniA.S.Ribavirin and interferonα-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 137ChengV.C.Clinical"/>
 <result pre="infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 137ChengV.C.Clinical management and" exact="infection" post="control of SARS: lessons learnedAntiviral Res.100201340741923994190 138FalzaranoD.Inhibition of novel"/>
 <result pre="replication by a combination of interferon-α2b and ribavirinSci. Rep.32013168623594967 139HuiD.S.Severe" exact="acute" post="respiratory syndrome vs. the Middle East respiratory syndromeCurr. Opin."/>
 <result pre="by a combination of interferon-α2b and ribavirinSci. Rep.32013168623594967 139HuiD.S.Severe acute" exact="respiratory" post="syndrome vs. the Middle East respiratory syndromeCurr. Opin. Pulm."/>
 <result pre="a combination of interferon-α2b and ribavirinSci. Rep.32013168623594967 139HuiD.S.Severe acute respiratory" exact="syndrome" post="vs. the Middle East respiratory syndromeCurr. Opin. Pulm. Med.20201423324124626235"/>
 <result pre="ribavirinSci. Rep.32013168623594967 139HuiD.S.Severe acute respiratory syndrome vs. the Middle East" exact="respiratory" post="syndromeCurr. Opin. Pulm. Med.20201423324124626235 140HaffizullaJ.Effect of nitazoxanide in adults"/>
 <result pre="Pulm. Med.20201423324124626235 140HaffizullaJ.Effect of nitazoxanide in adults and adolescents with" exact="acute" post="uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trialLancet"/>
 <result pre="study of nitazoxanide monotherapy for the treatment of patients with" exact="chronic hepatitis" post="C genotype 4Aliment. Pharmacol. Ther.28200857458018616643 142TanakaY.Suppression of coronavirus replication"/>
 <result pre="of nitazoxanide monotherapy for the treatment of patients with chronic" exact="hepatitis" post="C genotype 4Aliment. Pharmacol. Ther.28200857458018616643 142TanakaY.Suppression of coronavirus replication"/>
 <result pre="145DyallJ.Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273 146KindrachukJ.Antiviral potential of ERK/MAPK"/>
 <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273 146KindrachukJ.Antiviral potential of ERK/MAPK and"/>
 <result pre="potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East" exact="respiratory" post="syndrome coronavirus infection as identified by temporal kinome analysisAntimicrob."/>
 <result pre="of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory" exact="syndrome" post="coronavirus infection as identified by temporal kinome analysisAntimicrob. Agents"/>
 <result pre="ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome" exact="coronavirus infection" post="as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition"/>
 <result pre="and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus" exact="infection" post="as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition"/>
 <result pre="by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition of Middle East" exact="respiratory" post="syndrome coronavirus infection by anti-CD26 monoclonal antibodyJ. Virol.872013138921389924067970 148HuentelmanM.J.Structure-based"/>
 <result pre="temporal kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition of Middle East respiratory" exact="syndrome" post="coronavirus infection by anti-CD26 monoclonal antibodyJ. Virol.872013138921389924067970 148HuentelmanM.J.Structure-based discovery"/>
 <result pre="kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition of Middle East respiratory syndrome" exact="coronavirus infection" post="by anti-CD26 monoclonal antibodyJ. Virol.872013138921389924067970 148HuentelmanM.J.Structure-based discovery of a"/>
 <result pre="analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition of Middle East respiratory syndrome coronavirus" exact="infection" post="by anti-CD26 monoclonal antibodyJ. Virol.872013138921389924067970 148HuentelmanM.J.Structure-based discovery of a"/>
 <result pre="from a lethal Cryptosporidium parvum infectionAntimicrob. Agents Chemother.5720136063607324060869 152VermeireJ.J.Cure of" exact="hookworm infection" post="with a cysteine protease inhibitorPLoS Negl. Trop. Dis.62012e168022802972 153BurkardC.Atp1a1-mediated"/>
 <result pre="a lethal Cryptosporidium parvum infectionAntimicrob. Agents Chemother.5720136063607324060869 152VermeireJ.J.Cure of hookworm" exact="infection" post="with a cysteine protease inhibitorPLoS Negl. Trop. Dis.62012e168022802972 153BurkardC.Atp1a1-mediated"/>
 <result pre="proteinInt. J. Antimicrob. Agents52201873073229772395 155MilletJ.K.Host cell entry of middle east" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
 <result pre="J. Antimicrob. Agents52201873073229772395 155MilletJ.K.Host cell entry of middle east respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike proteinProc."/>
 <result pre="Natl. Acad. Sci. U. S. A.1112014152141521925288733 156AdedejiA.O.Novel inhibitors of severe" exact="acute" post="respiratory syndrome coronavirus entry that act by three distinctmechanismsJ."/>
 <result pre="Acad. Sci. U. S. A.1112014152141521925288733 156AdedejiA.O.Novel inhibitors of severe acute" exact="respiratory" post="syndrome coronavirus entry that act by three distinctmechanismsJ. Virol.8720138017802823678171"/>
 <result pre="Sci. U. S. A.1112014152141521925288733 156AdedejiA.O.Novel inhibitors of severe acute respiratory" exact="syndrome" post="coronavirus entry that act by three distinctmechanismsJ. Virol.8720138017802823678171 157AleksandraM.Entry"/>
 <result pre="lipid membranes: implications for the mechanism of action of broad-spectrum" exact="viral" post="fusion inhibitorsBiochem. J.459201416117024456301 167HollmannA.Effects of singlet oxygen generated by"/>
 <result pre="inhibitorsBiochem. J.459201416117024456301 167HollmannA.Effects of singlet oxygen generated by a broad-spectrum" exact="viral" post="fusion inhibitor on membrane nanoarchitectureNanomedicine1120151163116725791807 168XiaS.Peptide-based membrane fusion inhibitors"/>
 <result pre="simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with" exact="chronic" post="HCV genotypeJ Hepatol.622015104725596313 170MichaelL.K.GS-5734 and its parent nucleoside analog"/>
 <result pre="analog inhibit filo-, pneumo-, and paramyxovirusesSci. Rep.720174339528262699 171MichaelL.K.Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challengeSci. Transl.1120199242 Thanigaimalai Pillaiyar"/>
 <result pre="preparation of small molecules for various therapeutic targets such as" exact="heart" post="failure, hypertension and cancer. Acknowledgments M.M thank PSG Management"/>
 <result pre="small molecules for various therapeutic targets such as heart failure," exact="hypertension" post="and cancer. Acknowledgments M.M thank PSG Management for their"/>
</results>
